Literature DB >> 27238734

Drugs prescribed for patients hospitalized in a geriatric oncology unit: Potentially inappropriate medications and impact of a clinical pharmacist.

Coralie Deliens1, Gaétane Deliens2, Olivier Filleul3, Thierry Pepersack4, Ahmad Awada5, Martine Piccart6, Jean-Philippe Praet7, Lissandra Dal Lago8.   

Abstract

OBJECTIVES: The aim of this study was to assess the prevalence of potentially inappropriate medication (PIM) use upon admission and at discharge in a geriatric oncology unit after involving a clinical pharmacist. Although the few studies conducted in geriatric oncology units used the 2003 Beers criteria, this study used START and STOPP criteria, a more appropriate tool for European formularies.
MATERIALS AND METHODS: Prospective study in older (≥70years) patients consecutively admitted to a geriatric oncology unit in a cancer center from July 2011 to April 2012. Clinical pharmacist conducted a complete comprehensive medication review including non-prescription and complementary (herbals) medications. This information coupled with the patient's medical history allows identifying PIMs using the STOPP and START criteria. The number of PIMs at admission and at discharge from the hospital was compared after clinical pharmacist intervention.
RESULTS: Ninety-one older patients with cancer (mean age±SD=79±6years) were included in the study. START criteria identified 41 PIMs for 31 persons (34%) at admission compared to 7 PIMs for 6 persons (7%) at discharge. STOPP criteria identified 50 PIMs at admission for 29 persons (32%) compared to 16 PIMs at discharge for 14 persons (16%). Results showed significantly lower START scores at discharge than at admission (p<0.001); similarly, STOPP criteria demonstrated fewer PIMs at discharge than at admission (p<0.001).
CONCLUSION: The use of START and STOPP criteria by a clinical pharmacist allows identifying PIMs and changing prescriptions for older patients with cancer in agreement with the oncologist and geriatrician of the team.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Clinical pharmacist; Comprehensive medication review; Intervention; Older patients/elderly; Oncology; Polypharmacy; Potentially inappropriate medications; START criteria; STOPP criteria

Mesh:

Substances:

Year:  2016        PMID: 27238734     DOI: 10.1016/j.jgo.2016.05.001

Source DB:  PubMed          Journal:  J Geriatr Oncol        ISSN: 1879-4068            Impact factor:   3.599


  6 in total

1.  Research priorities to address polypharmacy in older adults with cancer.

Authors:  Ginah Nightingale; Mostafa R Mohamed; Holly M Holmes; Manvi Sharma; Erika Ramsdale; Grace Lu-Yao; Andrew Chapman
Journal:  J Geriatr Oncol       Date:  2021-02-13       Impact factor: 3.929

Review 2.  Advances in pain management for older patients with cancer.

Authors:  Georges El Hachem; Francisco Oliveira Rocha; Thierry Pepersack; Youssef Jounblat; Annie Drowart; Lissandra Dal Lago
Journal:  Ecancermedicalscience       Date:  2019-12-03

Review 3.  Managing Polypharmacy in Older Adults with Cancer Across Different Healthcare Settings.

Authors:  Andrew Whitman; Paige Erdeljac; Caroline Jones; Nicole Pillarella; Ginah Nightingale
Journal:  Drug Healthc Patient Saf       Date:  2021-04-29

Review 4.  Perspectives on functional status in older adults with cancer: An interprofessional report from the International Society of Geriatric Oncology (SIOG) nursing and allied health interest group and young SIOG.

Authors:  Ginah Nightingale; Nicolò Matteo Luca Battisti; Kah Poh Loh; Martine Puts; Cindy Kenis; Annette Goldberg; Kristen R Haase; Jessica Krok-Schoen; Gábor Liposits; Schroder Sattar; Petra Stolz-Baskett; Mackenzi Pergolotti
Journal:  J Geriatr Oncol       Date:  2020-11-07       Impact factor: 3.929

Review 5.  Workforce characteristics and interventions associated with high-quality care and support to older people with cancer: a systematic review.

Authors:  Jackie Bridges; Grace Lucas; Theresa Wiseman; Peter Griffiths
Journal:  BMJ Open       Date:  2017-07-31       Impact factor: 2.692

Review 6.  Functional Decline in the Cancer Patient: A Review.

Authors:  Jaidyn Muhandiramge; Suzanne G Orchard; Erica T Warner; Gijsberta J van Londen; John R Zalcberg
Journal:  Cancers (Basel)       Date:  2022-03-08       Impact factor: 6.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.